A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts

Blood

Volumn 104, Issue 7, 2004, Pages 2143-2148

  Abi Habib, Ralph J ^b   Liu, Shihui ^b   Bugge, Thomas H ^b   Leppla, Stephen H ^b   Frankel, Arthur E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DIPHTHERIA TOXIN; DIPHTHERIA TOXIN U2 GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR FUSION PROTEIN; FURIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; PROUROKINASE; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLAST CELL; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; IC 50; MACROPHAGE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN TARGETING; TOXIN STRUCTURE; TRANSLOCATION DOMAIN; UMBILICAL VEIN;

EID: 4644221124     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-01-0339     Document Type: Article

References (20)

1. Bennett JM, Kouides PA, Forman SJ. The myelodysplastic syndromes: morphology, risk assessment, and clinical management. Int J Hematol. 2002;76(suppl 2):228-238.
2. Choe S, Bennett MJ, Fujii G, et al. The crystal structure of diphtheria toxin. Nature. 1992;357:216-222.
3. VanderSpek JC, Murphy JR. Fusion protein toxins based on diphtheria toxin: selective targeting of growth factor receptor of eukaryotic cells. Methods Enzymol. 2000;327:239-249.
4. Frankel AE, Ramage J, Latimer A, et al. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for phase I clinical trials. Protein Expr Purif. 1999;16:190-201.
5. Perentesis JP, Bendel AE, Shao Y, et al. Granulocyte-macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias. Leuk Lymphoma. 1997;25:247-256.
6. Hogge DE, Willman CL, Kreitman RJ, et al. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein. Blood. 1998;92:589-595.
7. Hall PD, Willingham MC, Kreitman RJ, Frankel AE. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia. Leukemia. 1999;13:629-633.
8. Frankel AE, Powell BL, Hall PD, Case LD, Kreitman RJ. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res. 2002;8:1004-1013.
9. Liu S, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem. 2001;276:17976-17984.
10. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000;57:25-40.
11. Dano K, Romer J, Nielsen BS, et al. Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS. 1999;107:120-127.
12. Ramage J, Vallera DA, Black JH, Aplan PD, Kees UR, Frankel AE. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells. Leuk Res. 2003;27:79-84.
13. Kiser M, McCubrey JA, Steelman LS, et al. Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice. Leukemia. 2001;15:814-818.
14. Boyum A. Separation of white blood cells. Nature. 1964;204:793-794.
15. Frankel AE, Lilly M, Kreitman R, et al. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Blood. 1998;92:4279-4286.
16. Urieto JO, Liu T, Black JH, et al. Expression and purification of the recombinant diphtheria toxin DT388IL3 for phase I clinical trials. Protein Expr Purif. 2004;33:123-133.
17. Jardi M, Ingles-Esteve J, Burgal M, et al. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells. Thromb Haemost. 1996;76:1009-1019.
18. Tapiovaara H, Alitalo R, Stephens RW, Myohanen H, Ruutu T, Vaheri A. Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients. Blood. 1993;82:914-919.
19. Todhunter DA, Hall WA, Rastamzadeh E, Shu Y, Doumbia SO, Vallera DA. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model of glioblastoma. Protein Engineering Design and Selection. PEDS. 2004;17:157-164.
20. Schmidt M, Hynes NF, Groner B, Wels W. A bivalent single chain antibody-toxin specific for erbB-2 and the EGF receptor. Int J Cancer. 1996;65:538-546.